Suppr超能文献

使用低剂量钆喷酸葡胺(Gd-DTPA)的对比增强磁共振(MR)T1 映射在识别透明细胞肾细胞癌组织病理学分级和鉴别少脂性血管平滑肌脂肪瘤方面很有前景。

Contrast-enhanced magnetic resonance (MR) T1 mapping with low-dose gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) is promising in identifying clear cell renal cell carcinoma histopathological grade and differentiating fat-poor angiomyolipoma.

作者信息

Wang Shuai, Li Junheng, Zhu Diru, Hua Ting, Zhao Binghui

机构信息

Department of Radiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.

出版信息

Quant Imaging Med Surg. 2020 May;10(5):988-998. doi: 10.21037/qims-19-723.

Abstract

BACKGROUND

This study aimed to identify clear cell renal cell carcinoma (ccRCC) histopathological grade and differentiate it from fat-poor angiomyolipoma (AML). This was achieved through contrast-enhanced magnetic resonance (MR) T1 mapping with intravenous low-dose gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA).

METHODS

In total, 56 consecutive patients received MR scanning between January 2016 and December 2018 using the pre- and post- contrast-enhanced T1 mapping sequences with low-dose Gd-DTPA (0.036 mmol/kg). RCCs were pathologically proven in 40 patients after surgery and graded according to the International Society of Urological Pathology (ISUP) classification system. Ten AMLs were pathologically proven by surgery histopathology and six AMLs were diagnosed by magnetic resonance imaging (MRI). Patients were followed up for more than half a year. The mean T1 values of the renal lesion and ipsilateral normal renal parenchyma were measured before and after Gd-DTPA administration (T1p and T1e). The reduction of T1 value (T1d) and the ratio of its reduction (T1d %) were calculated and compared.

RESULTS

In 40 ccRCCs, higher-grade [International Society of Urologic Pathology (ISUP) grade 3 and 4] and lower-grade (ISUP grade 1 and 2) ccRCCs were noted in 13 and 27 patients, respectively. The mean T1p was 1,514.8±139.4 ms and the mean T1d was 907.7±193.7 ms in the higher-grade ccRCCs, which were significantly higher than in the lower-grade ccRCCs (T1p =1,251.7±151.5 ms and T1d =648.5±218.2 ms, respectively; P<0.001). Fat-poor AMLs had higher T1p (1,677.3±104.8 ms) and T1e (865.6±251.5 ms) as compared to ccRCCs (P<0.001). Combined T1p + T1d showed the highest area under the curve (AUC) (0.912) in the differentiation of higher-grade ccRCCs from lower-grade ccRCCs (P=0.010). Combined T1p + T1e had the highest AUC (0.956) in the differentiation between ccRCCs and fat-poor AMLs (P=0.010). All T1 mapping metrics could discriminate between normal renal parenchyma and renal lesions (P<0.001). No significant difference was found in the T1p and T1e at different parts of the ipsilateral normal renal parenchyma. Interobserver agreement for quantitative longitudinal relaxation time in the T1 maps was excellent.

CONCLUSIONS

Contrast-enhanced T1 mapping with low-dose Gd-DTPA may provide a more reliable and accurate approach in identifying ccRCCs histopathological grade and differentiating ccRCCs from fat-poor AMLs.

摘要

背景

本研究旨在明确肾透明细胞癌(ccRCC)的组织病理学分级,并将其与乏脂性肾血管平滑肌脂肪瘤(AML)相鉴别。这是通过静脉注射低剂量钆喷酸葡胺(Gd-DTPA)的对比增强磁共振(MR)T1 映射来实现的。

方法

2016 年 1 月至 2018 年 12 月期间,共有 56 例连续患者接受了 MR 扫描,采用了低剂量 Gd-DTPA(0.036 mmol/kg)的对比增强前后 T1 映射序列。40 例患者术后病理证实为 RCC,并根据国际泌尿病理学会(ISUP)分类系统进行分级。10 例 AML 通过手术组织病理学得到病理证实,6 例 AML 通过磁共振成像(MRI)诊断。对患者进行了半年以上的随访。在注射 Gd-DTPA 前后(T1p 和 T1e)测量肾病变和同侧正常肾实质的平均 T1 值。计算并比较 T1 值的降低量(T1d)及其降低率(T1d%)。

结果

在 40 例 ccRCC 中,13 例和 27 例患者分别为高级别[国际泌尿病理学会(ISUP)3 级和 4 级]和低级别(ISUP 1 级和 2 级)ccRCC。高级别 ccRCC 的平均 T1p 为 1514.8±139.4 ms,平均 T1d 为 907.7±193.7 ms,显著高于低级别 ccRCC(分别为 T1p =1251.7±151.5 ms 和 T1d =648.5±218.2 ms;P<0.001)。与 ccRCC 相比,乏脂性 AML 的 T1p(1677.3±104.8 ms)和 T1e(865.6±251.5 ms)更高(P<0.001)。联合 T1p + T1d 在区分高级别 ccRCC 和低级别 ccRCC 方面曲线下面积(AUC)最高(0.912)(P =0.010)。联合 T1p + T1e 在区分 ccRCC 和乏脂性 AML 方面 AUC 最高(0.956)(P =0.010)。所有 T1 映射指标均可区分正常肾实质和肾病变(P<0.001)。同侧正常肾实质不同部位的 T1p 和 T1e 未发现显著差异。T1 图中定量纵向弛豫时间的观察者间一致性良好。

结论

低剂量 Gd-DTPA 的对比增强 T1 映射可能为识别 ccRCC 的组织病理学分级以及区分 ccRCC 和乏脂性 AML 提供一种更可靠、准确的方法。

相似文献

引用本文的文献

1
B1 corrected T1 mapping in the differentiation and prediction of breast cancer.
Sci Rep. 2025 Aug 21;15(1):30785. doi: 10.1038/s41598-025-15590-9.
2
Identification of benign from malignant small renal tumors: is there a possible role of T1 mapping?
Discov Oncol. 2025 May 19;16(1):808. doi: 10.1007/s12672-025-02609-w.
5
PRIMERS: Polydopamine Radioimmunotherapy with Image-Guided Monitoring and Enhanced Release System.
Pharmaceutics. 2024 Nov 20;16(11):1481. doi: 10.3390/pharmaceutics16111481.
7
Potential of quantitative T1 mapping to serve as a novel prognostic predictor of clear cell renal cell carcinoma after nephrectomy.
Quant Imaging Med Surg. 2024 Oct 1;14(10):7600-7611. doi: 10.21037/qims-23-1829. Epub 2024 Sep 26.
9
T1 mapping in evaluation of clinicopathologic factors for rectal adenocarcinoma.
Abdom Radiol (NY). 2024 Jan;49(1):279-287. doi: 10.1007/s00261-023-04045-2. Epub 2023 Oct 15.

本文引用的文献

4
Cancer statistics, 2018.
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
6
Gadolinium Retention and Toxicity-An Update.
Adv Chronic Kidney Dis. 2017 May;24(3):138-146. doi: 10.1053/j.ackd.2017.03.004.
7
Use of Radiocontrast Agents in CKD and ESRD.
Semin Dial. 2017 Jul;30(4):290-304. doi: 10.1111/sdi.12593. Epub 2017 Apr 5.
8
Contrast enhanced renal MR angiography at 7 Tesla: How much gadolinium do we need?
Eur J Radiol. 2017 Jan;86:76-82. doi: 10.1016/j.ejrad.2016.11.007. Epub 2016 Nov 5.
9
Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review.
J Cardiovasc Magn Reson. 2016 Nov 30;18(1):89. doi: 10.1186/s12968-016-0308-4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验